Last $41.78 USD
Change Today -0.47 / -1.11%
Volume 747.6K
DXCM On Other Exchanges
DXCM is not on other exchanges.
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $49.83
52 Week Low
09/27/13 - $25.49
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DEXCOM INC (DXCM)

dexcom inc (DXCM) Related Businessweek News

No Related Businessweek News Found

dexcom inc (DXCM) Details

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. It offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. The company’s ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments, as well as DexCom SHARE, a remote monitoring system, which provides secondary notification and does not replace real time continuous glucose monitoring or standard home blood glucose monitoring. Its in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. The company also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. It markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. The company was founded in 1999 and is headquartered in San Diego, California.

646 Employees
Last Reported Date: 02/20/14
Founded in 1999

dexcom inc (DXCM) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $420.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $325.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $237.0K
Chief Technical Officer
Total Annual Compensation: $284.9K
Executive Vice President of Strategy and Corp...
Total Annual Compensation: $284.9K
Compensation as of Fiscal Year 2013.

dexcom inc (DXCM) Key Developments

Insulet Corporation and DexCom to Develop CGM-Integrated Diabetes Manager

Insulet Corporation and DexCom, Inc. have agreed to develop a CGM-integrated personal diabetes manager. This will allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System. That platform to enable glucose and pump data to be displayed on a smartphone.

DexCom, Inc. Announces Data Integration Relationship with Asante Solutions, Inc

Asante Solutions, Inc. and DexCom, Inc. announced their intention to enable the Dexcom mobile app platform, which is currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump. This will be the second insulin delivery device to be integrated into the Dexcom mobile app, which is designed to aggregate glucose and other diabetes-related data from patients' devices and display the integrated data on a smartphone. In June, Dexcom announced its intention to maintain an 'open architecture' approach to diabetes-related data which will include an ‘Authorized by Dexcom’ mark to indicate the compatibility of devices and apps integrating Dexcom CGM data.

DexCom, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

DexCom, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $58.2 million compared to $35.8 million a year ago. Operating loss was $5.8 million compared to $9.9 million a year ago. Net loss was $6.0 million or $0.09 per diluted share compared to $10.1 million or $0.14 per basic and diluted share a year ago. For the six months, the company reported total revenue of $105.9 million compared to $65.4 million a year ago. Operating loss was $18.1 million compared to $20.8 million a year ago. Net loss was $18.5 million or $0.25 per basic and diluted share compared to $21.2 million or $0.30 per basic and diluted share a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $41.78 USD -0.47

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insulet Corp $37.09 USD -0.78
Merge Healthcare Inc $2.37 USD -0.04
NeuStar Inc $25.59 USD -0.93
Radview Software Ltd $0.0031 USD 0.00
Tandem Diabetes Care Inc $13.43 USD -0.56
View Industry Companies

Industry Analysis


Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.6x
Price/Book 31.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at